Home

Articles

Genetically Engineered Animals and Public Health

GE animals are being developed to transform and improve public health.

The Role of Intellectual Property in Global Health

BIO is committed to increased access to biologic medicines for patients throughout the world. 

Patent Reform Passes the Senate and Moves to the House

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

2013 Policy Principles to Promote Biotechnology

Biotechnology helps societies solve old problems in new ways. Through the science of using living cells and the discovery of new molecules, biotech innovation provides societies with innovative means to address their most urgent needs: fighting disease, feeding the hungry, and improving the environment.

ISAAA Report Finds 100-Fold Increase in Global Biotech Crop Plantings Since 1996

According to the ISAAA report for 2012, farmers around the world continue to enthusiastically embrace and adopt genetically engineered (GE) crops because of their tremendous environmental and economic benefits and contribution to food security.

The BIO CEO & Investor Conference

Recently BIO hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference is the largest investor conference focused on for established and emerging publicly traded and select private biotech companies.

The 340B Drug Discount Program

Congress created the 340B program in 1992 to help uninsured indigent patients gain better access to prescription medicines. This white paper examines the history and original intent of the program as well as highlights key findings to help policymakers ensure that the 340B program meets its stated purpose and to provide a roadmap for next steps to be considered.

Biotech in China

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

Renewing the Project BioShield Act

In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear (CBRN) attacks.

BIO Sponsorship Brings New Meaning to the Term “Double Helix”

BIO’s sponsorship opportunities provide industry leaders with heightened visibility through “Double Helix” and “Helix” sponsorships.

Jumpstart Our Business Startups (JOBS) Act: Impact on the Biotechnology Industry

President Obama signed the Jumpstart Our Business Startups (JOBS) Act into law on April 5, 2012. BIO advocated strongly for this new law, which includes several important policies designed to stimulate capital formation for growing businesses.

Data Exclusivity Protects Innovators and Assures Investors

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time.

One-on-One Meetings and Business Development

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

Product Launch Stewardship: Food and Agriculture Section

Through its advocacy efforts, BIO’s Food and Agriculture Section supports a regulatory framework that facilitates and enables the development and commercialization of new biotechnology-derived plant products.

Build Your Brand with BIO: Sponsor an Event in 2013

Now is the time to start planning your business goals for 2013 and one of the best ways to achieve those goals is through sponsoring BIO’s global events. Through sponsoring with BIO, your organization can:

Clinical Trials Modernization Initiative

In an effort to bring innovative new medicines to patients more efficiently, while protecting and enhancing patient safety, BIO is developing an initiative to modernize clinical trials.

Focus on Rheumatology, Inflammation, Anesthesia, & Pain: July 2012

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

Focus on Oncology: July 2012

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

Focus on Neurology & CNS: July 2012

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

Focus on Nephrology, Endocrinology, Metabolism, & Gastroenterology: July 2012

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

Focus on Cardiology, Pulmonology, & Blood: July 2012

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

Focus on Allergy, Infectious Disease, & Antiviral: July 2012

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

Venture Capital Critical in SBIR Implementation

SBIR/STTR Reauthorization will restore eligibility to majority VC-backed emerging companies

Personalized Medicine and Diagnostics (PMDx) Working Group Mission Statement

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients.

Building Biotech Hubs; Biomanufacturing Attractors and Accelerators

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.